Gestalt receives approval for software in Europe
Spokane-based startup Gestalt Diagnostics recently received eight patents in the United Kingdom for its PathFlow software that replaces glass slides and microscopes with data-rich digital images.
In addition to the new patents, the company received clearance for clinical use of the software throughout Europe. The PathFlow technology has been approved in the U.S. for research purposes only and likely won’t see FDA approval until 2024.
“We’re a startup, so it’s great validation that what we’re doing is cutting-edge and we’re at the front of what’s happening in our space,” said Dan Roark, CEO of Gestalt.